Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2014 | ASH 2014: Phase Ib study of daratumumab in combination with backbone regimens in myeloma

Maria-Victoria Mateos • 6 Dec 2014
ASH 2014
Multiple Myeloma Antibodies Bortezomib Daratumumab Dexamethasone Melphalan Prednisone Thalidomide

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Maria-Victoria Mateos discusses an open-label, multicentre, phase Ib study of the safety, tolerability and dose regimen of the anti-CD38 monoclonal antibody, daratumumab, in combination with backbone regimens in patients with multiple myeloma. Backbone regimens include bortezomib-dexamethasone, bortezomib-thalidomide-dexamethasone, bortezomib-melphalan-prednisone and pomalidomide-dexamethasone.

More from Maria-Victoria Mateos

2:44
Dual-targeting bispecific antibody alnuctamab in R/R multiple myeloma
Maria-Victoria Mateos • 9 Dec 2023
2:26
Preliminary results of GEM2017FIT: comparing induction therapies in fit elderly patients with MM
Maria-Victoria Mateos • 9 Dec 2023
4:21
CAR-T in multiple myeloma: progress in the space and what can be done to improve patient outcomes
Maria-Victoria Mateos • 17 Feb 2024
Latest advances in T-cell engaging therapies for multiple myeloma
Adam Cohen et al. • 15 Apr 2023

Related Videos

Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
Molecular characteristics associated with increased risk of disease progression in SMM
Mark Bustoros • 27 Sep 2023
The content of VJHemOnc is intended for healthcare professionals